Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PTPRE antisense RNA 1 (PTPRE-AS1) is a long noncoding RNA (lncRNA) located antisense to the protein-coding gene PTPRE (receptor-type tyrosine-protein phosphatase epsilon). It is selectively upregulated in IL-4–stimulated macrophages and functions as a negative regulator of M2 macrophage activation by enhancing the expression of PTPRE through epigenetic mechanisms involving recruitment of the WDR5 histone methyltransferase complex and trimethylation of H3K4 at the PTPRE promoter. PTPRE-AS1 deficiency leads to increased M2 macrophage polarization and related inflammation, while also modulating susceptibility to allergic disease and colitis. Its expression and functional effects implicate it as an important regulator of inflammatory responses, but not as a conventional therapeutic target like a receptor, enzyme, or transporter[1][2][3].
Epigenetic modulation via binding to WDR5, facilitating H3K4me3 at the PTPRE promoter, which enhances PTPRE expression and impacts downstream MAPK/ERK signaling in macrophages[1][2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PTPRE antisense RNA 1 (PTPRE-AS1).